Urine Drug Screen/Toxicology Interpretation Note

Patient: [Full name] — [MRN]

Collection Date/Time: [Date and time / Unknown]

Specimen Type: [urine / oral fluid / blood / hair / other]

Test Type: [presumptive immunoassay screen / definitive LC-MS/MS / definitive GC/MS / point-of-care immunoassay / other]

Observed Collection: [yes / no / unknown]

Ordering Clinician: [Name and credentials]

Result Date: [Date / Pending]

Indication for Testing

[Clinical indication and context for testing] (Examples: routine monitoring for chronic opioid therapy, MOUD monitoring, safety monitoring per clinic policy, baseline prior to initiating controlled substances, follow-up after prior unexpected result, evaluation of clinical concern. If indication is unclear from order, state that interpretation is based on current treatment context.)

Medication and Substance Reconciliation

Prescribed Controlled Substances: [Medications with dose and frequency] (Include patient-reported timing of last dose if available. Note which medications or metabolites should be detectable on the ordered panel.)

Patient-Reported Substance Use: [Reported use of alcohol, cannabis, illicit substances, or other relevant substances with timing and frequency] (If patient was not interviewed or information unavailable, state this explicitly.)

Relevant Clinical Factors: [Factors materially affecting interpretation] (Examples: renal/hepatic impairment, recent anesthesia, extreme hydration or diuretic use, medications known to cross-react. Omit this field entirely if none relevant.)

Specimen Validity

(Include this section only if laboratory reports validity parameters or flags a concern. Omit entirely if validity testing was not performed and no concerns exist.)

• Creatinine: [Value and units]
• Specific Gravity: [Value]
• pH: [Value]
• Other Validity Markers: [Oxidants, nitrites, temperature, or other if reported]
• Lab Validity Interpretation: [valid / dilute / adulterated / substituted / invalid]
• Impact on Interpretation: [How validity affects result interpretation]
• Clinical Response: [Repeat testing / observed collection / defer actions pending repeat / other]

Results

Analyte/Drug Class	Result	Method	Expected	Clinical Comment
[Analyte or drug class]	[negative / positive / quantitative value with units]	[screen / confirmatory]	[yes / no]	[Brief comment for unexpected findings] (Leave blank if not needed.)

[2–3 sentence narrative summary] (State overall concordance with prescribed medications and reported use, highlight key unexpected findings, and indicate whether results are final or confirmatory testing is pending.)

Interpretation

(Use neutral, non-accusatory language throughout. Drug testing cannot determine dose, exact timing, route of administration, or impairment.)

Expected Findings: [Brief confirmation of results consistent with prescribed regimen and reported substance use]

Unexpected Findings:

• [Unexpected finding]: [What is unexpected and why]

  • Differential explanations: [Assay limitations/cutoffs, timing relative to detection window, metabolism or cross-reactivity, specimen dilution/validity, possible nonprescribed use or nonadherence]
  • Clinical significance: [Safety risks, drug–drug interactions, adherence concerns, relapse concerns if in SUD treatment]
  • Recommended clarification: [Confirmatory testing, repeat testing with observed collection, PDMP review, collateral information]

(Add additional items for each unexpected result. Explicitly state if interpretation is limited by pending confirmatory results, specimen validity concerns, or incomplete history.)

Assessment

(Summarize clinical implications in order of safety priority. Distinguish confirmed findings from suspected or uncertain findings.)

• Medication adherence: [confirmed / likely / uncertain / not supported] — [Brief rationale]
• Nonprescribed substance exposure: [confirmed / suspected / not evident] — [Associated risk and context]
• Overdose/sedation risk: [low / moderate / high] — [Note high-risk combinations if present]
• Treatment engagement or relapse concerns: [Summary in neutral language] (Include only if applicable.)
• Data quality limitations: [Specimen validity issues, pending confirmations, incomplete history] (Include only if applicable.)

Plan

Patient Communication: [in person / phone / telehealth / secure message / not yet discussed] — [Patient's explanation for unexpected findings if provided] (Note counseling was delivered in nonjudgmental, safety-focused manner. If not yet discussed, document plan to review at next visit.)

Medication Management:

• [continue / adjust / hold / discontinue] [Medication name and dose] — [Rationale]
• Naloxone: [offered and accepted / offered and declined / already prescribed / not indicated]

(Avoid abrupt discontinuation unless medically necessary for safety; document reasoning if immediate changes required. If no changes needed, state current regimen continues unchanged.)

Monitoring:

• Visit frequency: [no change / increased / decreased] — [Rationale if changed]
• Testing frequency: [no change / increased / decreased] — [Include plan for observed collection if indicated]
• PDMP review: [performed / not performed] — [Pertinent findings if performed]

Referrals: [Addiction medicine / Behavioral health / Pain management / Higher level of care / None indicated]

Follow-up: [Next appointment timeframe] — [Plan for reviewing pending confirmatory results including who will review and how patient will be notified]

Signature: [Clinician name, credentials] — [Date and time]

Preliminary interpretation—subject to revision when definitive results finalize. (Include only if confirmatory testing is pending.)